YOLFTbeta
30

Protia Inc.

303360 · KQ · Healthcare / Diagnostics & Research

2,810.00KRW+55.00 (+2.00%)

Price History

Full chart

Market Stats

Previous Close2,755.00
Open2,775.00
Day Range2,765.00 – 2,860.00
52-Week Range3,680.00 – 6,890.00
Volume47.63K
Market Cap77.66B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.18
50-Day Avg5,091.50
200-Day Avg4,981.68

About

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Kook Jin Lim
  • HeadquartersA-702, 401 Yangcheon-ro, Seoul, South Korea, 07528, Korea
  • Websitehttps://www.protia.co.kr

Leadership

  • Mr. Kook Jin LimCEO & Director · b. 1961

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue7.64B8.23B10.51B15.12B
Growth (%)-+7.64%+27.79%+43.80%
Cost of Revenue3.02B4.15B4.24B5.82B
Gross Profit4.62B4.08B6.27B9.30B
Gross Margin60.46%49.58%59.68%61.53%
Operating Expense3.56B3.92B4.77B5.58B
Operating Income1.06B164.09M1.50B3.72B
Operating Margin13.83%1.99%14.28%24.61%
EBITDA1.72B948.08M2.78B4.70B
EBITDA Margin22.47%11.52%26.44%31.08%
Net Income1.25B462.94M2.44B4.47B
Net Income Margin16.39%5.63%23.23%29.57%
R&D1.22B1.24B1.68B2.06B
R&D as % of Total Revenue15.96%15.02%16.00%13.65%
Interest Expense10.69M10.82M6.71M11.78M
Interest Expense % of Total Revenue0.14%0.13%0.06%0.08%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets17.41B25.14B27.86B33.03B
Total Liabilities1.42B1.61B1.65B2.33B
Total Equity15.99B23.53B26.21B30.70B
Cash2.10B1.72B2.83B2.96B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.22B381.42M1.44B3.00B
Capital Expenditure165.80M1.73B1.17B1.12B
Free Cash Flow1.05B-1.34B261.32M1.88B
FCF to OCF86.38%-352.26%18.20%62.55%

Earnings

Report DateJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------
EPS Actual11.5838.10-0.807.3976.7027.2178.3255.4361.0899.87130.5875.76120.15
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap77.66B
Enterprise Value55.33B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.38
Price / Book2.08
Revenue (TTM)17.75B
Gross Profit (TTM)10.91B
EBITDA5.15B
Profit Margin30.98%
Operating Margin30.61%
Return on Equity18.04%
Return on Assets8.96%
Shares Outstanding12.88M
Shares Float7.39M
Beta0.18
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 13, 20261.5:1
  • Jul 21, 20202:1